(Q38340008)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

Umberto Leone Roberti Maggiore

29 February 2020

main subject

phase II clinical trial

0 references

author

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Simone Ferrero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Giorgia Mangili

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

9

Massimo Candiani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Alice Bergamini

1

0 references

author name string

Emanuela Rabaiotti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Riccardo Viganò

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Micaela Petrone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Patrizia De Marzi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Stefano Salvatore

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

1 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

345-362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer.

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The contribution of BRCA1 and BRCA2 to ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Novel therapies, including enzastaurin, in the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

PARP inhibitors in ovarian cancer: current status and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Targeted anti-vascular therapies for ovarian cancer: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Incorporation of pazopanib in maintenance therapy of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Novel tyrosine kinase inhibitors for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

WEE1 tyrosine kinase, a novel epigenetic modifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Pralatrexate pharmacology and clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Ganetespib and HSP90: translating preclinical hypotheses into clinical promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Antibody-based immunotherapy for ovarian cancer: where are we at?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Structural, functional and therapeutic biology of survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Monoclonal antibodies therapies for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

New perspectives in ovarian cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.999154

10.1517/13543784.2015.999154

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25640877%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference